Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Longeviti develops and commercializes implantable neurosurgical devices.
Abcuro develops immunotherapies to treat autoimmunity and cancer.
Blue Earth Therapeutics is a radiopharmaceutical company that specializes in the advancement of radiotherapeutics to treat cancer patients.
Q'Apel Medical designs access device technology for neurovascular interventions and unmet clinical needs.
CervoMed a clinical-stage firm focused on discovering therapies for brain degenerative illnesses.
Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.
Septerna is a biotech firm unlocking diverse drug discovery potential in G protein-coupled receptors across various diseases.
TwinStrand Biosciences develops and commercializes the duplex sequencing technology for DNA sequencing.
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Field Trip Health is providing simple, evidence-based therapies for healing and heightening engagement with the world.
Soleus Capital has invested in 34 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Soleus Capital's top investment sectors include Health Care, Medical, Biotechnology, Therapeutics, Medical Device. The firm invests across 14 different industry categories.
Among tracked funding rounds, Abcuro received $200.0M in a Series C round. Soleus Capital's total known invested capital is $2.8B.
Soleus Capital's average investment size is $81.2M across its portfolio of 34 companies.
Recent Soleus Capital portfolio additions include Longeviti, Abcuro, Blue Earth Therapeutics, Q'Apel Medical, CervoMed. These companies were founded in 2020 or later.